Advertisement

Virchows Archiv

, Volume 446, Issue 5, pp 475–482 | Cite as

NF-kB in development and progression of human cancer

  • Xavier Dolcet
  • David Llobet
  • Judit Pallares
  • Xavier Matias-Guiu
Review Article
First Online:
Received:
Accepted:

Abstract

The nuclear factor kB (NF-kB) comprises a family of transcription factors involved in the regulation of a wide variety of biological responses. NF-kB plays a well-known function in the regulation of immune responses and inflammation, but growing evidences support a major role in oncogenesis. NF-kB regulates the expression of genes involved in many processes that play a key role in the development and progression of cancer such as proliferation, migration and apoptosis. Aberrant or constitutive NF-kB activation has been detected in many human malignancies. In recent years, numerous studies have focused on elucidating the functional consequences of NF-kB activation as well as its signaling mechanisms. NF-kB has turned out to be an interesting therapeutic target for treatment of cancer.

Keywords

NF-kB Cancer Apoptosis 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

Supported by grants FISS 01/1656, FISS PI020227, SAF 2004-05250 and 2002XT00115. X.D. holds a postdoctoral fellowship supported by Department d’Universitats, Recerca i Societat de la Informació, Generalitat de Catalunya (2003RED0018). J.P. holds a research fellowship from the Fondo de Investigaciones Sanitarias, Ministerio de Sanidad y Consumo (BEFI-02/9007). DLL holds a research fellowship from AECC-Catalunya contra el Cancer-Lleida.

References

  1. 1.
    Bash J, Zong WX, Gelinas C (1997) c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition. Mol Cell Biol 17:6526–6536Google Scholar
  2. 2.
    Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280–288Google Scholar
  3. 3.
    Bullani RR, Huard B, Viard-Leveugle I, Byers HR, Irmler M, Saurat JH, Tschopp J, French LE (2001) Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 117:360–364Google Scholar
  4. 4.
    Caamano JH, Perez P, Lira SA, Bravo R (1996) Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo. Mol Cell Biol 16:1342–1348Google Scholar
  5. 5.
    Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT (1999) Mutations in the IkBa gene in Hodgkin’s disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 18:3063–3070Google Scholar
  6. 6.
    Canoz O, Rassidakis GZ, Admirand JH, Medeiros LJ (2004) Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. Mod Pathol 17:911–917Google Scholar
  7. 7.
    Charalambous MP, Maihofner C, Bhambra U, Lightfoot T, Gooderham NJ (2003) Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells. Br J Cancer 88:1598–1604Google Scholar
  8. 8.
    Chen F, Castranova V, Shi X (2001) New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 59:387–397Google Scholar
  9. 9.
    Chen F, Wang M, O’Connor JP, He M, Tripathi T, Harrison LE (2003) Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappa beta. J Cell Biochem 90:732–744Google Scholar
  10. 10.
    Chen QM, Tu VC (2002) Apoptosis and heart failure: mechanisms and therapeutic implications. Am J Cardiovasc Drugs 2:43–57Google Scholar
  11. 11.
    Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr (2000) Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19:1123–1131Google Scholar
  12. 12.
    Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905–2927Google Scholar
  13. 13.
    Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17:2215–2223Google Scholar
  14. 14.
    Duyao MP, Kessler DJ, Spicer DB, Bartholomew C, Cleveland JL, Siekevitz M, Sonenshein GE (1992) Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B. J Biol Chem 267:16288–16291Google Scholar
  15. 15.
    Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS Jr (1997) Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 272:24113–24116Google Scholar
  16. 16.
    Gilmore TD (1999) Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 18:6925–6937Google Scholar
  17. 17.
    Greten FR, Karin M (2004) The IKK/NF-kappaB activation pathway—a target for prevention and treatment of cancer. Cancer Lett 206:193–199Google Scholar
  18. 18.
    Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161:2833–2840Google Scholar
  19. 19.
    Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785–5799Google Scholar
  20. 20.
    Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195–2224Google Scholar
  21. 21.
    Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA (2003) Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin.Oncogene 22:1955–1964Google Scholar
  22. 22.
    Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M (1999) NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19:2690–2698Google Scholar
  23. 23.
    Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C (2001) Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed–Sternberg cells. Blood 97:2798–2807Google Scholar
  24. 24.
    Holmes-McNary M, Baldwin AS Jr (2000) Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 60:3477–3483Google Scholar
  25. 25.
    Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N, Offit K, Chaganti RS (1996) REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 87:25–29Google Scholar
  26. 26.
    Houldsworth J, Olshen AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, Qin J, Palanisamy N, Shen Y, Dyomina K, Petlakh M, Pan Q, Zelenetz AD, Dalla-Favera R, Chaganti RS (2004) Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood 103:1862–1868Google Scholar
  27. 27.
    Hsia CY, Cheng S, Owyang AM, Dowdy SF, Liou HC (2002) c-Rel regulation of the cell cycle in primary mouse B lymphocytes. Int Immunol 14:905–916Google Scholar
  28. 28.
    Irisarri M, Plumas J, Bonnefoix T, Jacob MC, Roucard C, Pasquier MA, Sotto JJ, Lajmanovich A (2000) Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin’s lymphoma B cell line. Leukemia 14:2149–2158Google Scholar
  29. 29.
    Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190–195Google Scholar
  30. 30.
    Joos S, Otano-Joos MI, Ziegler S, Bruderlein S, du Manoir S, Bentz M, Moller P, Lichter P (1996) Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87:1571–1578Google Scholar
  31. 31.
    Jungnickel B, Staratschek-Jox A, Brauninger A, Spieker T, Wolf J, Diehl V, Hansmann ML, Rajewsky K, Kuppers R (2000) Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin’s lymphoma. J Exp Med 191:395–402Google Scholar
  32. 32.
    Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621–663Google Scholar
  33. 33.
    Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382–22387Google Scholar
  34. 34.
    Kim KM, Lee YJ (2004) Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene (in press)Google Scholar
  35. 35.
    Kreuz S, Siegmund D, Scheurich P, Wajant H (2001) NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 21:3964–3973Google Scholar
  36. 36.
    La Rosa FA, Pierce JW, Sonenshein GE (1994) Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol 14:1039–1044Google Scholar
  37. 37.
    Lee JU, Hosotani R, Wada M, Doi R, Kosiba T, Fujimoto K, Miyamoto Y, Tsuji S, Nakajima S, Nishimura Y, Imamura M (1999) Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer 35:1374–1380Google Scholar
  38. 38.
    Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947Google Scholar
  39. 39.
    Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J,Arguelles R, Machin P, Prat J (2001) Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32:569–577Google Scholar
  40. 40.
    Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, Baldwin AS Jr (1997) Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278:1812–1815Google Scholar
  41. 41.
    Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J (2001) NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 21:5299–5305Google Scholar
  42. 42.
    Migliazza A, Lombardi L, Rocchi M, Trecca D, Chang CC, Antonacci R, Fracchiolla NS, Ciana P, Maiolo AT, Neri A (1994) Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood 84:3850–3860Google Scholar
  43. 43.
    Mosialos G (1997) The role of Rel/NF-kappa B proteins in viral oncogenesis and the regulation of viral transcription. Semin Cancer Biol 8:121–129Google Scholar
  44. 44.
    Mukhopadhyay T, Roth JA, Maxwell SA (1995) Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 11:999–1003Google Scholar
  45. 45.
    Nair A, Venkatraman M, Maliekal TT, Nair B, Karunagaran D (2003) NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22:50–58Google Scholar
  46. 46.
    Neri A, Chang CC, Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RS, Dalla-Favera R (1991) B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell 67:1075–1087Google Scholar
  47. 47.
    Neri A, Fracchiolla NS, Roscetti E, Garatti S, Trecca D, Boletini A, Perletti L, Baldini L, Maiolo AT, Berti E (1995) Molecular analysis of cutaneous B-and T-cell lymphomas. Blood 86:3160–3172Google Scholar
  48. 48.
    Norris JL, Baldwin AS Jr (1999) Oncogenic Ras enhances NF-kappaB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. J Biol Chem 274:13841–13846Google Scholar
  49. 49.
    Ohno H, Takimoto G, McKeithan TW (1990) The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 60:991–997Google Scholar
  50. 50.
    Olsson A, Diaz T, Aguilar-Santelises M, Osterborg A, Celsing F, Jondal M, Osorio LM (2001) Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 15:1868–1877Google Scholar
  51. 51.
    Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X (2004) Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol 204:569–577Google Scholar
  52. 52.
    Panka DJ, Mano T, Suhara T, Walsh K, Mier JW (2001) Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276:6893–6896Google Scholar
  53. 53.
    Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18:6013–6020Google Scholar
  54. 54.
    Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Offit K, Jhanwar SC, Chaganti RS (1998) Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 92:234–240Google Scholar
  55. 55.
    Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938–6947Google Scholar
  56. 56.
    Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr (1998) A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 12:968–981Google Scholar
  57. 57.
    Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, Cardiff RD, Sonenshein GE (2003) Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 23:5738–5754Google Scholar
  58. 58.
    Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M, Katano M (2001) Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 7:4136–4142Google Scholar
  59. 59.
    Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293:1495–1499Google Scholar
  60. 60.
    Solan NJ, Miyoshi H, Carmona EM, Bren GD, Paya CV (2002) RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem 277:1405–1418Google Scholar
  61. 61.
    Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952–2960Google Scholar
  62. 62.
    Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, Reed JC (1998) A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 273:7787–7790Google Scholar
  63. 63.
    Thomas RP, Farrow BJ, Kim S, May MJ, Hellmich MR, Evers BM (2002) Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery 132:127–134Google Scholar
  64. 64.
    Thornburg NJ, Pathmanathan R, Raab-Traub N (2003) Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 63:8293–8301Google Scholar
  65. 65.
    Toth CR, Hostutler RF, Baldwin AS Jr, Bender TP (1995) Members of the nuclear factor kappa B family transactivate the murine c-myb gene. J Biol Chem 270:7661–7671Google Scholar
  66. 66.
    Vasudevan KM, Gurumurthy S, Rangnekar VM (2004) Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 24:1007–1021Google Scholar
  67. 67.
    Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680–1683Google Scholar
  68. 68.
    Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin AS Jr (2001) The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol 21:8428–8436Google Scholar
  69. 69.
    Xiao G, Cvijic ME, Fong A, Harhaj EW, Uhlik MT, Waterfield M, Sun SC (2001) Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J 20:6805–6815Google Scholar
  70. 70.
    Yamamoto Y, Gaynor RB (2001) Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 1:287–296Google Scholar
  71. 71.
    Yamamoto Y, Yin MJ, Lin KM, Gaynor RB (1999) Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274:27307–27314Google Scholar
  72. 72.
    Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77–80Google Scholar
  73. 73.
    Yu Q, Geng Y, Sicinski P (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017–1021Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Xavier Dolcet
    • 1
  • David Llobet
    • 1
  • Judit Pallares
    • 1
  • Xavier Matias-Guiu
    • 1
  1. 1.Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de VilanovaUniversity of LleidaLleidaSpain

Personalised recommendations

Cite article

Buy options